In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Stephen Liu discusses daily highlights from the conference.

Dr. Caicun Zhou discusses the results of ivonescimab versus pembrolizumab in the first-line HARMONi-2 study. Dr. Tina Cascone discusses preliminary outcomes from the perioperative NeoCOAST-2 study, and Dr. Marina Chiara Garassino outlines the potential QCS-NMR TROP2 biomarker using data from TROPION-Lung01. Dr. Matthew Smeltzer shares the results of the 2024 IASLC Global Survey on Biomarker Testing and how they compare to findings from the previous survey in 2018.

Guests:

Dr. Tina Cascone

Physician-Scientist and Associate Professor, Department of Thoracic/Head and Neck Medical Oncology

University of Texas MD Anderson Cancer Center in Houston, Texas

Dr. Marina Chiara Garassino

Director, Thoracic Oncology Program and Professor of Medicine

University of Chicago

Dr. Matthew Smeltzer

Associate Professor, Division of Epidemiology, Biostatistics, and Environmental Health

University of Memphis

Professor Caicun Zhou

Chief Physician and Director of the Department of Medical Oncology

Tongji University in Shanghai Pulmonary Hospital